CNR Institutional Research Information System

EVANGELISTI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 974
NA - Nord America 768
SA - Sud America 183
EU - Europa 155
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 2
Totale 2.105
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 731
SG - Singapore 402
CN - Cina 248
BR - Brasile 153
VN - Vietnam 98
HK - Hong Kong 83
KR - Corea 47
FR - Francia 45
IT - Italia 33
CA - Canada 21
IN - India 19
BD - Bangladesh 14
JP - Giappone 13
AR - Argentina 12
DE - Germania 10
FI - Finlandia 10
NL - Olanda 10
IL - Israele 9
CO - Colombia 8
GB - Regno Unito 8
ES - Italia 7
ID - Indonesia 7
EC - Ecuador 6
IQ - Iraq 6
ZA - Sudafrica 6
PL - Polonia 5
TR - Turchia 5
JM - Giamaica 4
PH - Filippine 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
IE - Irlanda 3
MX - Messico 3
SA - Arabia Saudita 3
AT - Austria 2
AU - Australia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
SE - Svezia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TN - Tunisia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 2.094
Salva come PNG Salva come JPEG
Città #
Santa Clara 280
Singapore 231
Hefei 109
Hong Kong 80
San Jose 79
Ashburn 49
Seoul 47
Beijing 46
Ho Chi Minh City 38
Lauterbourg 38
Hanoi 27
Los Angeles 27
New York 17
São Paulo 17
Chicago 11
Buffalo 10
Dallas 9
Helsinki 9
Rio de Janeiro 9
Houston 8
Minamishinagawa 6
Montreal 6
Newark 6
Phoenix 6
Chennai 5
Da Nang 5
Orem 5
Atlanta 4
Baghdad 4
Baltimore 4
Bengaluru 4
Council Bluffs 4
Istanbul 4
Tokyo 4
Warsaw 4
Boardman 3
Brooklyn 3
Curitiba 3
Dublin 3
Hải Dương 3
Kingston 3
Quito 3
Rialto 3
San Francisco 3
Seattle 3
Toronto 3
Biên Hòa 2
Bogotá 2
Buenos Aires 2
Cape Town 2
Charlotte 2
Chino 2
Colombo 2
Cà Mau 2
Denver 2
Dhaka 2
Feira de Santana 2
Frankfurt am Main 2
Goiânia 2
Hampton 2
Hangzhou 2
Iporá 2
Lombard 2
Maceió 2
Medellín 2
Milan 2
Modena 2
Mount Wolf 2
Nha Trang 2
Niš 2
Norristown 2
North Charleston 2
Nova Iguaçu 2
Nuremberg 2
Padova 2
Paracatu 2
Paris 2
Pilar 2
Pittsburgh 2
Pretoria 2
Providence 2
Richmond 2
Salvador 2
San Miguel 2
Santos 2
Shanghai 2
Staten Island 2
The Bronx 2
The Dalles 2
Thái Bình 2
Tucson 2
Venice 2
Zephyrhills 2
Zurich 2
'Asir Region 1
Abbottabad 1
Acalanes Ridge 1
Ahmedabad 1
Albany 1
Allegan 1
Totale 1.347
Salva come PNG Salva come JPEG
Nome #
Lamin A and Prelamin a Counteract Migration of Osteosarcoma Cells 104
The role played by wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia 100
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B. 85
Advances in targeting signal transduction pathways. 76
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 74
Elevated TGF beta 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 70
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 64
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 61
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 60
The emerging multiple roles of nuclear Akt. 58
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 56
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 55
The unfolded protein response: A novel therapeutic target in acute leukemias 52
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines 51
Potential therapeutic effects of the mtor inhibitors for preventing ageing and progeria-related disorders. 50
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 50
Therapeutic targeting of CK2 in acute and chronic leukemias 49
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 48
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 47
GSK-3: a multifaceted player in acute leukemias 46
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update 45
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 44
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 43
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 43
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 42
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 41
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 40
Targeting the cancer initiating cell: The ultimate target for cancer therapy 39
Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway 38
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 38
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. 37
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 36
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 34
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: Targeting the unfolded protein response signaling 34
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins 34
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. 33
Autophagy in acute leukemias: A double-edged sword with important therapeutic implications 33
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 29
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response 29
Current treatment strategies for inhibiting mTOR in cancer 28
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; Indications for novel therapeutics 28
DGKzeta is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. 28
GSK-3beta: A key regulator of breast cancer drug resistance (Comment on: Sokolosky M, et al. Cell Cycle 2014; 13:820-33;) 28
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. 25
Totale 2.105
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.487
article - articoli 7.487
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.974
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 1 0 0 1
2024/2025783 6 4 56 27 233 56 11 49 23 9 153 156
2025/20261.104 72 111 86 228 176 46 150 46 49 73 26 41
2026/2027216 50 53 113 0 0 0 0 0 0 0 0 0
Totale 2.105